AstraZeneca’s biologics arm, MedImmune, recently announced that it has partnered with the world’s largest diabetes research and clinical care organization to develop new drugs for treatment of diabetes, obesity and related metabolic disorders. The company announced that it has entered a three-year research collaboration with Joslin Diabetes Center. Together, MedImmune …